The objective of this study is the collection of demographic data (like sex and age), medical data and treatment information during, and until 6 weeks after a hospital submission for heart failure.By doing this, a good insight will be gained for…
ID
Source
Brief title
Condition
- Heart failures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Prevalence of iron deficiency according to the definition of the ESC guidelines
Secondary outcome
- Associations between type and measures of severity of heart failure and iron
deficiency;
- Time course of measures of iron (deficiency), heart failure and
co-morbidities
Background summary
In 2012 the European Society of Cardiology (ESC) published in her Guideline for
acute and chronic heart failure a definition for iron deficiency.
The prevalence of iron deficiency according to this definition has not been
sufficiently studied in a real life setting.
Study objective
The objective of this study is the collection of demographic data (like sex and
age), medical data and treatment information during, and until 6 weeks after a
hospital submission for heart failure.
By doing this, a good insight will be gained for this group of recently
admitted hart failure patients, on the prevalence of iron deficiency in acute
heart failure, based on data from blood samples taken.
Study design
An observational, epidemiological cohort study
Study burden and risks
At 3 moments in a period of approximately 16 weeks, blood samples will be
analysed for assessing the iron deficiency. Bloodsample collecting will be
done during an bloodsampling moment that is already necessary for regular
treatment of patient
There is no extra burden or risk for the patient.
Westbroek 43
Breda 4822 ZX
NL
Westbroek 43
Breda 4822 ZX
NL
Listed location countries
Age
Inclusion criteria
Hospitalisation due to acute heart failure
Exclusion criteria
- History of erythropoietin stimulating agent, IV iron therapy, and/or blood
transfusion in previous 3 months prior to hospitalisation.
- Oral iron therapy at any dose and/or continious use of iron containing
multivitamines in previous 4 weeks prior to hospitalisation.
- History of receiving systemic chemotherapy and/or radiotherapy in previous 3
months prior to hospitalisation.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL59894.096.16 |
| OMON | NL-OMON28189 |